trending Market Intelligence /marketintelligence/en/news-insights/trending/MjW00v-hNb2IF_y5ELa-OA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Antibe Therapeutics prices securities offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Antibe Therapeutics prices securities offering

Antibe Therapeutics Inc. priced a "best efforts" offering of its units at 10 Canadian cents apiece for minimum gross proceeds of C$3 million and maximum gross proceeds of C$5 million.

The units will be made up of 1 common share and 0.5 three-year purchase warrant. Each whole warrant will allow the holder to buy 1 Antibe share at 15 cents apiece.

The offering's underwriters can purchase up to an additional 15% of the units sold; the offering is meant to raise funds for the company's lead drug ATB-346. If the company raises the maximum amount, it will also direct funds toward the development of ATB-352.

Bloom Burton Securities Inc., Dominick Inc. and Echelon Wealth Partners Inc. are acting as the co-agents of the offering.